주 메뉴 바로가기 본문 바로가기 하단 바로가기

New Medicines

We create high-end pharmaceutical products
with our outstanding biopharmaceutical R&D capabilities

New Drugs

Drug Development
through Partnership

Celltrion is actively engaged in licensing in/out through strategic partnerships with the industry, academia, and research centers to expand its pipelines. Through these partnerships, we plan to boost the effectiveness of our new drug R&D projects and revitalize the bio ecosystems in and outside of Korea.

  • Licensing in

    Celltrion works with universities, research centers, and pharmaceutical firms in open innovation projects to secure candidate substances for new drugs and biosimilars under development, and other technologies and intellectual property rights.

  • Licensing out

    Celltrion provides our partners with technologies and intellectual property rights in candidate substances for new drugs and biosimilars, and secure publishing rights, in joint or commissioned research projects.

  • Co-development

    Celltrion works with our partners to increase the chances of success in candidate substance development, reduce development cost, and mitigate other possible risks

CDMO

Contract Development and Management Organization (CDMO) is a co-development model where participants offer and share their expertise in development/production/clinical trial/approval and development costs. Our CDMO partners can commercialize candidate substances for new drugs faster by tapping into our capabilities while we enjoy the benefit of securing the rights to use the substances before others. All in all, CDMO promises faster and dynamic growth for all parties involved.

  • Select candidate
    molecule
  • Cell Line Development
  • Optimization of cell culture and purification process
  • Analytical method development and quality evaluation
  • Formulation development
  • clinical·non-clinical material
    manufacturing
  • Clinical study design
    IND packages
  • Commercial production